Raymond James Financial Inc. Decreases Stake in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Raymond James Financial Inc. reduced its stake in Teva Pharmaceutical Industries by 8.4%, holding approximately 1.6 million shares valued at $24.87 million after selling 147,486 shares in the 1st quarter.
• Multiple institutional investors, including Dimensional Fund Advisors and Stifel Financial Corp., have recently increased their stakes in Teva, with some seeing significant increases up to 148.3% during the fourth quarter.
• Teva's stock received favorable ratings from various research firms, with price targets raised by Bank of America and JPMorgan, resulting in an average consensus rating of "Buy" and a price target of $24.71.

Raymond James Financial Inc. decreased its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 8.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,618,107 shares of the company's stock after selling 147,486 shares during the quarter. Raymond James Financial Inc. owned approximately 0.14% of Teva Pharmaceutical Industries worth $24,870,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in TEVA. Dimensional Fund Advisors LP lifted its stake in Teva Pharmaceutical Industries by 13.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,611,743 shares of the company's stock worth $57,568,000 after purchasing an additional 313,817 shares during the last quarter. Stifel Financial Corp lifted its stake in Teva Pharmaceutical Industries by 33.3% during the fourth quarter. Stifel Financial Corp now owns 88,478 shares of the company's stock worth $1,950,000 after purchasing an additional 22,087 shares during the last quarter. Hsbc Holdings PLC lifted its stake in Teva Pharmaceutical Industries by 5.7% during the fourth quarter. Hsbc Holdings PLC now owns 561,289 shares of the company's stock worth $12,374,000 after purchasing an additional 30,155 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Teva Pharmaceutical Industries by 148.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,049,388 shares of the company's stock worth $45,170,000 after purchasing an additional 1,223,957 shares during the last quarter. Finally, Capital Analysts LLC purchased a new stake in Teva Pharmaceutical Industries during the fourth quarter worth approximately $102,000. Hedge funds and other institutional investors own 54.05% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on TEVA. Bank of America boosted their target price on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. UBS Group cut their price target on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a research report on Thursday, June 26th. The Goldman Sachs Group started coverage on Teva Pharmaceutical Industries in a research note on Friday, June 6th. They issued a "buy" rating and a $24.00 price objective for the company. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and boosted their price objective for the company from $21.00 to $23.00 in a research note on Monday, May 12th. Finally, Truist Financial started coverage on Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries currently has an average rating of "Buy" and a consensus price target of $24.71.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $18.14 on Tuesday. The business's 50-day moving average price is $16.76 and its 200 day moving average price is $16.28. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $22.80. The company has a market capitalization of $20.81 billion, a PE ratio of -113.38, a price-to-earnings-growth ratio of 1.09 and a beta of 0.62. The company has a current ratio of 1.06, a quick ratio of 0.77 and a debt-to-equity ratio of 2.45.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The firm had revenue of $4.18 billion for the quarter, compared to analyst estimates of $4.34 billion. During the same period last year, the company earned $0.61 EPS. The firm's quarterly revenue was up .3% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, research analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of the firm's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total value of $105,626.12. Following the sale, the executive vice president directly owned 9,989 shares of the company's stock, valued at approximately $170,012.78. This trade represents a 38.32% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Placid Jover sold 6,053 shares of the firm's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $91,763.48. Following the completion of the sale, the insider directly owned 6,774 shares in the company, valued at approximately $102,693.84. The trade was a 47.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 65,001 shares of company stock valued at $996,958. Insiders own 0.55% of the company's stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.